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The incidence of nonalcoholic fatty liver disease (NAFLD) 
is skyrocketing in both developed and developing coun-
tries due, in large part, to the increased prevalence of 
obesity. NAFLD is the hepatic manifestation of metabolic 
syndrome and is accompanied by increased FFAs in circula-
tion. These increased free fatty acids (FFAs) are due to ex-
cessive adipose tissue lipolysis and are toxic to cells in the 
liver, heart, and pancreas (1, 2). Hepatocyte lipoapoptosis 
due to increased circulating FFAs is recognized as a hall-
mark of nonalcoholic steatohepatitis (NASH), a severe 
form of NAFLD. In addition to hepatocyte injury, cholestatic 
NAFLD has been suggested to develop at least in a subset of 
patients with NAFLD (3). In support of this notion, we have 
recently demonstrated that biliary epithelial cells, or chol-
angiocytes, undergo lipoapoptosis upon saturated FFA 
exposure. Saturated FFAs triggered activation of stress ki-
nases, like p38 and ERK. We also found that FFA-induced 
cholangiocyte lipoapoptosis was dependent on the fork-
head family of transcription factor class O (FoxO)3, and, in 
part, its downstream target, p53-upregulated modulator of 
apoptosis (PUMA) (4, 5).
MicroRNAs are noncoding small RNAs that mediate 
posttranscriptional regulation of mRNA transcript levels 
and protein translation. They have been shown to play an 
important role in a variety of cellular processes, includ-
ing apoptosis. In particular, miR-34a is a pro-apoptotic 
microRNA that decreases expression of several cell survival 
proteins (6–9). Additionally, miR-34a expression is induced 
by p53 at the promoter level to increase apoptosis (10, 11). 
miR-34a has been suggested to modulate apoptosis through 
the SIRT1/p53 pathway (9, 12, 13). NAFLD and NASH 
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patients have elevated levels of pro-apoptotic miR-34a in 
the circulation and the liver. Increased miR-34a levels were 
also shown to be associated with the severity of NASH in 
patients (14, 15). However, the exact role for miR-34a in 
cholangiocyte lipoapoptosis is unknown.
In the present study, we hypothesized that miR-34a is im-
portant in cholangiocyte lipoapoptosis. We explored the 
critical role for miR-34a during cholangiocyte lipoapopto-
sis induced by palmitate (PA). Treatment of cholangiocytes 
with PA induced the expression of miR-34a, reduced ex-
pression of several miR-34a target proteins, and increased 
lipoapoptosis. We also identified miR-34a as a novel target 
of FoxO3.
MATERIALS AND METHODS
Materials
Palmitic acid (#P5585) and fatty acid-free BSA (#A3803) were 
obtained from Sigma-Aldrich, St. Louis, MO. Magnetic protein G 
beads (#S1430S) were purchased from New England Bio Labs, 
Ipswich, MA. Trizol reagent and all other chemicals were obtained 
from Thermo Fisher Scientific, Waltham, MA.
Animals
All procedures involving animals in this work were approved 
by the IACUC at the University of Nebraska Medical Center. 
C57BL/6J mice (4–6 weeks old) were randomly divided into two 
groups and fed either control diet (17.2% kcal from fat, 100 g/kg 
sucrose) or high-fat high-sucrose (HFHS) diet (42% kcal from 
fat with 54% saturated and 9.7% trans-fat, 0.4% cholesterol, and 
340 g/kg sucrose) for 3 months. Water was given ad libitum and 
the HFHS mice were fed sucrose-containing water (40 g/l) to 
mimic the Western diet, as described (16).
Masson trichrome staining
Liver tissues were formalin-fixed, paraffin embedded, and 
stained for Masson trichrome reaction by the Tissue Sciences core 
facility at the University of Nebraska Medical Center.
Antibodies
Rabbit antiserum against FoxO3 (2497), cleaved caspase 3 
(C9661), and cleaved poly (ADP-ribose) polymerase (PARP) 
(P9542) were from Cell Signaling. Rabbit antiserum against 
PUMA (28226) was from Santa Cruz. Goat anti-lamin B (sc-6216) 
and mouse anti-actin (sc-1615) were purchased from Sigma. 
Peroxidase-conjugated secondary antisera were from Jackson 
Immuno Research laboratory.
Cell lines and treatment
H69, a human normal immortalized cholangiocyte cell line, was 
grown in DMEM supplemented with 10% FBS, insulin (5 g/ml), 
adenine (24.3 g/ml), epinephrine (1 g/ml), triiodothyronine-
transferrin (triiodothyronine, 2.23 ng/ml; transferrin, 8.19 g/ml), 
epidermal growth factor (9.9 ng/ml), and hydrocortisone (5.34 
g/ml). KMCH, Mz-ChA-1 and HuCCT-1 (human cholangiocar-
cinoma cell lines), MDA-KKA2 (mouse cholangiocyte cell line), 
and Huh7 (hepatoma cell line) were grown in DMEM supple-
mented with 10% FBS, insulin (0.5 g/ml), and G418 (50 g/ml) 
(5). H69, KMCH, HuCCT, Mz-ChA-1, Huh7, and MDAKK-2 cells 
were treated with the indicated concentrations of FFAs (400–800 
M) dissolved fresh in isopropanol at 100× and added to pre-
warmed medium containing 1% fatty acid-free BSA for 24 h. 
Vehicle treatment was isopropanol with a final concentration 
of 1% in the medium. The SIRT1 inhibitor, EX527, was used at 
100 M and the receptor tyrosine kinase (MET) inhibitor, Su11274, 
was used at 2 M.
Measurement of apoptosis
Percent apoptosis was quantified by characteristic nuclear mor-
phology visualized by treatment with DNA-binding dye, DAPI, as 
described before (6, 7). Briefly, cells were stained with 5 g/ml 
DAPI for 20–30 min at 37°C. Images were obtained under UV 
epifluorescence microscopy using a Leica DMI6000B inverted 
microscope. Apoptotic nuclei (condensed, fragmented) were 
counted and presented as a percent of total nuclei. At least 100 
cells were counted per well and experiments were performed in 
triplicate. Caspase 3/7 activity was measured by enzymatic fluoro-
phore release (Apo-ONE) according to the manufacturer’s instruc-
tions (Promega) and were represented as fold-change compared 
with vehicle treatment, with experiments performed in quadrupli-
cate as described (5).
Nuclear isolation and Western blot analysis
Nuclear extracts were prepared as described (17). Cell lysates 
containing 30 g of protein were resolved by SDS-PAGE. Proteins 
were transferred to a nitrocellulose membrane and visualized by 
immunoblotting.
Lentiviral shRNA transduction
shRNA silencing lentiviral pLKO.1-puro vector targeting FoxO3 
and control GFP were obtained from Sigma and stable transfec-
tions were carried out as described (5). FoxO3 shRNA #1 and #2 
target the nucleotide sequences 2185-2205 and 1626-1648 of 
FoxO3 mRNA (NM_001455.1), respectively.
Isolation and quantitation of miR-34a
Cellular RNA and total liver RNA were isolated using lysis in 
chaotropic salt and acid:phenol:chloroform extraction (mirVana 
kit; Life Technologies). Total RNA (100 ng) was used to amplify 
miRs using hydrolysis probe and stem loop primers for miR-34a 
(hsa-miR-34a-5p, #PN4427975-000426) and Z30 control RNA 
(#PN4427975-001092). Relative expression was calculated using 
the delta CT method.
miR-34a mimic and locked nucleic acid transfection
H69 and KMCH cells were transfected for 24 h with negative 
control A, a nontargeting control locked nucleic acid (LNA) oli-
gonucleotide, or LNA-34a (250999-B) obtained from Exiqon. 
Cells were then treated with vehicle or PA (800 M) for another 
24 h and apoptotic markers were measured as described above. 
For miR-34a targets, cells were transfected with either miR-34a 
mimic (to replicate fatty acid-induced expression) or antagonist 
(LNA-34a) for 24 h followed by protein isolation.
Statistics
Data are expressed as mean ± SEM. Statistical analysis was per-
formed using one-way ANOVA with Bonferroni post hoc correc-
tion. P < 0.05 was considered to be statistically significant.
RESULTS
Evidence for PA-induced cholangiocyte lipoapoptosis
Our earlier report had established that cholangiocytes 
undergo lipoapoptosis upon FFA exposure (5). We treated 
normal immortalized and malignant cholangiocytes with 
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PA (800 M) for 24 h and measured caspase 3/7 activa-
tion. H69 cells showed a 10-fold increase in caspase 3/7 
activity with PA treatment compared with vehicle (Fig. 1A). 
Cholangiocyte cell lines, HuCCT, KMCH, and Mz-ChA-1, 
showed a 20-fold, 9-fold, and 8-fold increase in caspase 3/7 
activity, respectively, with PA treatment compared with ve-
hicle (Fig. 1B–D). We tested PA concentrations from 0 to 
800 M and found increased apoptosis in KMCH cells over 
400 M (Fig. 1E) or over 200 M in Mz-ChA-1 cells (Fig. 
1F). In addition to caspase activation, we assessed the cas-
pase cleavage products, PARP and caspase 3 itself. PARP is 
a 116 kDa protein with a role in DNA repair, chromatin 
structure formation, and differentiation. Increased caspase 
3/7 activity with PA treatment was accompanied by an in-
crease in the levels of 85 kDa cleaved PARP and cleaved 
caspase 3 in cholangiocytes (Fig. 1G). We have reported 
that the pro-apoptotic protein, PUMA, a downstream tar-
get of FoxO3 was induced by PA and was partly responsible 
for cholangiocyte lipoapoptosis (5). Here, we tested the 
expression of PUMA with PA treatment in different chol-
angiocyte cell lines and found that the expression was 
increased in H69, HuCCT, KMCH, and Mz-ChA-1 cells 
treated with PA compared with cells treated with vehicle 
(Fig. 1H). These results suggest that treatment with PA, 
comparable to pathophysiological levels found in NASH 
patients, induced cholangiocyte lipoapoptosis.
PA induced miR-34a expression
To further evaluate the mechanism of cholangiocyte lipo-
apoptosis, we tested the role of the pro-apoptotic microRNA, 
miR-34a, in cholangiocyte lipoapoptosis. miR-34a was cho-
sen because it was elevated in the liver and circulation from 
patients with NASH or diabetes (14, 15, 18). We analyzed 
miR-34a expression upon exposure to a lower concentra-
tion of PA (400 M instead of 800 M). We know that 400–
800 M PA induces a concentration-dependent increase in 
cell death (5), so initially we chose the lower concentration 
to minimize RNA loss from apoptosis. We found that miR-
34a levels were significantly increased in human cholangio-
cyte cell lines, H69, Mz-ChA-1, KMCH, and HuCCT, treated 
with 400 M PA (Fig. 2A–D). To test the generality of our 
finding, we used a mouse cholangiocyte cell line, MDA-
KKA2. PA treatment showed an increase in miR-34a ex-
pression relative to vehicle-treated MDA-KKA2 cells (Fig. 
2E). We next tested to determine whether PA also induced 
an increase in miR-34a expression in hepatocytes. A hepa-
toma cell line, Huh7, was treated with 400 M PA for 24 h 
and miR-34a expression levels were measured. Similar to 
cholangiocytes, we observed that PA treatment induced ex-
pression of miR-34a in this hepatocyte-derived cell line 
(Fig. 2F). PA treatment of KMCH cells at 400, 600, or 800 
M progressively increased miR-34a levels (Fig. 2G). To-
gether, these results suggest that PA induces the expression 
Fig. 1. PA induced cholangiocyte lipoapoptosis. Cell 
lines were treated with PA (800 M) or vehicle (Veh) 
for 24 h. A–D: Caspase 3/7 activity was significantly in-
creased in PA-treated cells. Data represent the mean ± 
SEM for n = 4. *P < 0.05, compared with vehicle by t-
test. KMCH cells (E) and Mz-ChA-1 cells (F) treated 
with PA (0–800 M) showed a significant concentra-
tion-dependent increase in caspase 3/7 activity. Data 
represent the mean ± SEM for n = 4. ***P < 0.05, com-
pared with vehicle; statistical comparison was by 
ANOVA with post hoc correction. G: Cleaved PARP 
and cleaved caspase 3 levels were increased in whole-
cell lysates taken from PA-treated cells compared with 
vehicle-treated (V) cells. H: PUMA protein was also 
increased by PA treatment.
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of miR-34a in both cholangiocytes and hepatocytes, possi-
bly contributing to lipoapoptosis.
Anti-miR-34a protects cholangiocyte lipoapoptosis
To test the role of miR-34a in cholangiocyte lipoapopto-
sis, we transfected H69 and KMCH cells with antisense 
LNA against miR-34a (anti-miR-34a) or negative control 
before challenging with PA. Treatment with PA induced 
cholangiocyte lipoapoptosis in H69 and KMCH cells trans-
fected with negative control, as evidenced by an increase in 
percent apoptotic nuclei and caspase 3/7 activity (Fig. 3). 
H69 cells transfected with anti-miR-34a showed a signifi-
cant decrease in percent apoptotic nuclei and caspase 3/7 
activity with PA treatment (Fig. 3A). Similarly, anti-miR-34a 
transfected KMCH cells showed a significant decrease in 
PA-induced cholangiocyte lipoapoptosis (Fig. 3B). These 
results suggest an important role for miR-34a in PA-induced 
cholangiocyte lipoapoptosis.
FoxO3 is critical for miR-34a expression
Our earlier report demonstrated a critical role of FoxO3 
in cholangiocyte lipoapoptosis (5). Here, we tested to de-
termine whether FoxO3 is required for the induction of 
miR-34a during PA lipotoxicity. PA-treated H69 and KMCH 
cells showed an increase in nuclear FoxO3 levels after 16 h 
(Fig. 4A). Transduction with FoxO3 shRNA in H69 and 
KMCH cells resulted in knockdown of FoxO3 protein, as 
compared with control GFP shRNA transduced cells (Fig. 
4B, C). Control shRNA- and FoxO3 shRNA-transduced 
cells were treated with 600 M PA or vehicle for 24 h and 
miR-34a levels were analyzed by quantitative RT-PCR. PA 
significantly induced the expression of miR-34a in H69 
cells transduced with control shRNA. However, increased 
miR-34a expression due to PA treatment was abolished 
in FoxO3 shRNA-transduced cells (Fig. 4D). Similarly, the 
induction of miR-34a by PA was significantly abrogated in 
KMCH cells transduced with FoxO3 shRNA (Fig. 4E). 
These data suggest that FoxO3 is a novel transcriptional 
regulator of miR-34a.
miR-34a target expression
The mRNAs of SIRT1, MET, and Kruppel-like factor 4 
(KLF4) comprise of noncanonical and canonical seed 
binding sites for miR-34a (6, 9, 12, 13, 19–22). We then as-
sessed expression levels of these anti-apoptotic proteins af-
ter 16 or 24 h of PA treatment. The levels of SIRT1 in H69 
cells were found to be decreased after 16 or 24 h with 800 
M PA treatment compared with vehicle (Fig. 5A). H69 
cells also showed a decrease in MET expression after 16 
and 24 h of PA treatment (Fig. 5A). Levels of KLF4 were 
also lower in H69 cells treated with PA. Similarly, KMCH 
and HuCCT cells showed a decrease in the expression of 
SIRT1, MET, and KLF4 with 800 M of PA treatment at the 
16 and 24 h time points (Fig. 5B, C). We next tested to de-
termine whether this was also true for the Huh7 hepatocyte 
cell line. Treatment with 800 M PA led to a decrease in 
the expression of SIRT1 and MET, both after the 16 and 
24 h time points. We did not find any expression of KLF4 
in Huh7 cells and the absence of KLF4 was previously ob-
served in proteomic studies of Huh7 cells (23, 24).
Levels of SIRT1 were decreased in Mz-ChA-1 cells after 
16 or 24 h of PA treatment (Fig. 5E). -Klotho and fibro-
blast growth factor receptor (FGFR)1 have been shown to 
be targets of miR-34a (25). Further, FGFR1 and FGFR4 are 
dependent on the coreceptor, -klotho (26). Both FGFR1 
and FGFR4 levels were decreased in cells exposed to PA 
after 16 or 24 h of treatment (Fig. 5E). We were unable to 
identify a sensitive and specific antibody to detect -klotho 
protein.
Increasing PA concentrations decreased the protein levels 
of SIRT1, MET, and KLF4. In Mz-ChA-1 cells, SIRT1 did 
not show large expression changes (Fig. 5F), while MET 
Fig. 2. Induction of miR-34a by PA. A–F: Cell lines (cholangio-
cyte- or cholangiocarcinoma-derived: H69, Mz-ChA-1, KMCH, 
HuCCT, and MDA-KKA2; hepatoma-derived: Huh7) were treated 
with PA (400 M) or vehicle (Veh) for 24 h. This lower concentra-
tion was chosen to limit cell death from PA allowing reliable RNA 
isolation. Relative expression of pro-apoptotic miR-34a was signifi-
cantly elevated in PA-treated cholangiocytes and hepatocytes. miR-
34a was quantified by RT-PCR and normalized to Z30 for human 
cell lines or RNU6 for mouse MDA-KKA2 cells. G: The full concen-
tration range of PA from 200 to 800 M was tested in KMCH cells 
and showed increased levels of miR-34a with an increasing concen-
tration of PA. Data represent the mean ± SEM for n = 4. *P < 0.05, 
t-test.
870 Journal of Lipid Research Volume 58, 2017
was progressively decreased with increasing the concentra-
tion of PA (Fig. 5F). In KMCH cells, increasing PA de-
creased SIRT1, MET, and KLF4, especially at 600–800 M 
(Fig. 5G). For Fig. 5F, G, the caspase inhibitor ZVAD-FMK 
was included (10 M) to limit loss of cells to lipoapoptosis. 
The decrease in multiple cellular proteins was specific, as 
we did not observe a decrease in actin, and observed an 
increase in PUMA levels upon PA treatment. These results 
suggest that miR-34a upregulation with PA treatment has 
many cellular targets and decreases the levels of cell sur-
vival proteins, like SIRT1, MET, KLF4, FGFR1, and FGFR4, 
potentially contributing to cholangiocyte lipoapoptosis.
miR-34a target validation
We next wanted to further validate miR-34a targets by 
transfecting miR-34a mimic and anti-miR-34a in Mz-ChA-1 
Fig. 3. Anti-miR-34a protected against PA-induced 
cholangiocyte lipoapoptosis. A, B: miR-34a was antago-
nized by transfecting cells with LNA-34a (anti-miR-
34a; filled bars) compared with nontargeting negative 
control A LNA (Neg Con; open bars). Twenty-four 
hours later, cells were treated with PA (800 M) or ve-
hicle (Veh) for 24 h. PA-induced cholangiocyte lipo-
apoptosis was measured by nuclear morphology (left) 
and by caspase 3/7 activity (right). Data represent the 
mean ± SEM for n = 4. *P < 0.001, compared with ve-
hicle; #P < 0.001, compared with Neg Con with PA 
treatment; statistical comparison was by ANOVA with 
post hoc correction.
Fig. 4. FoxO3 induced miR-34a expression. A: Nu-
clear extracts were prepared from H69 or KMCH cells 
treated with vehicle (Veh) or PA for 24 h. FoxO3 and 
lamin B were detected by immunoblot. B, C: Cell lines 
(H69 or KMCH) were transduced with shRNA to GFP 
or FoxO3 (two shRNAs, indicated as #1 or #2) and 
stably-transfected cells selected by antibiotic resistance. 
Whole-cell FoxO3 protein levels were compared with 
actin. D, E: GFP shRNA- or FoxO3 shRNA-transduced 
cells were treated with PA (600 M; filled bars) or ve-
hicle (Veh; open bars) for 24 h. miR-34a levels were 
normalized to Z30. Data represent the mean ± SEM 
for n = 4. *P < 0.05, compared with vehicle; #P < 0.05 
compared with PA-treated GFP shRNA cells; ANOVA 
with post hoc correction.
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and KMCH cells. The miR-34a LNA antagonist decreased 
miR-34a expression by approximately 91% in Mz-ChA-1 
cells (Fig. 6A). The miR-34a mimic decreased the expres-
sion of SIRT1, MET, and KLF4 in Mz-ChA-1 cells compared 
to negative-control transfected cells (Fig. 6B). Cells trans-
fected with anti-miR-34a did not have dramatically altered 
levels of these proteins (Fig. 6B). KMCH cells transfected 
with miR-34a mimic showed a similar decrease in SIRT1, 
MET, and KLF4 (Fig. 6B). When cells were transfected with 
LNA-34a followed by PA treatment (800 M), the miR-34a 
antagonist partially prevented loss of SIRT1 and MET (Fig. 
6C, D). To test whether loss of function of either of these 
proteins contributes to lipoapoptosis, we treated KMCH 
cells with the SIRT1 inhibitor, EX527, or the MET kinase 
inhibitor, Su11274, followed by 400 M PA. The lower PA 
concentration was chosen to allow for detection of sensiti-
zation to PA. The SIRT1 inhibitor, either alone or in com-
bination, increased lipoapoptosis, while the MET inhibitor 
did not alter caspase 3/7 activation (Fig. 6E). Together, 
cells transfected with miR-34a mimic to increase miR-34a 
in the absence of PA treatment showed a decrease in pre-
dicted target proteins, such as SIRT1, MET, and KLF4. An-
tagonism of miR-34a partially protected from this loss, 
while inhibition of SIRT1 plus PA treatment exacerbated 
cell death.
Cholangiocyte lipoapoptosis in HFHS-fed mice
C57BL/6 mice were fed with control or HFHS diet for 
3 months. Liver sections were analyzed with Masson trichrome 
staining for the detection of chicken-wire-like collagen ac-
cumulation. Liver sections obtained from HFHS-fed mice 
showed lipid droplet and collagen accumulation compared 
with control-fed mice (Fig. 7A). We isolated liver total RNA 
and found that miR-34a levels were significantly upregu-
lated in HFHS diet-fed mice compared with controls (Fig. 
7B). Next, we co-stained formalin-fixed liver sections with 
pan-keratin (a bile duct marker) and TUNEL for the quan-
titation of apoptotic cholangiocytes. We observed elevated 
cholangiocyte lipoapoptosis in HFHS-fed mice (Fig. 7C). 
Our data provide evidence for the upregulation of hepatic 
Fig. 5. PA decreased SIRT1, MET, and KLF4. A–D: Cells were 
treated with PA (800 M) or vehicle (V) for 16 or 24 h. SIRT1, MET, 
and KLF4 protein expression was detected by immunoblot, com-
pared with actin control. E: Cells were treated as in (A–D) and 
SIRT1, FGFR1, or FGFR4 was detected by immunoblot compared 
with actin control. F, G: Increasing PA (400, 600, or 800 M) was 
added to Mz-ChA-1 or KMCH cells and SIRT1, MET, and KLF4 pro-
teins were measured by immunoblot.
Fig. 6. miR-34a decreased SIRT1, MET, and KLF4 protein expres-
sion. A: LNA-34a decreased miR-34a levels by 91% in Mz-ChA-1 cells 
24 h after transfection. B: Mz-ChA-1 or KMCH cells were transfected 
with negative control A LNA (Neg Con), microRNA mimic (miR-
34a), or anti-miR-34a (LNA-34a) for 24 h. SIRT1, MET, and KLF4 
expression was detected by immunoblot in whole-cell lysates. C, D: 
SIRT1 and MET loss in response to PA was measured in cells trans-
fected with negative control A LNA (Neg Con) or miR-34a antago-
nist (LNA-34a). E: Lipoapoptosis in response to a low PA stimulus 
was tested in the presence of DMSO vehicle, Su11274 MET inhibi-
tor (2 M), EX527 SIRT1 inhibitor (100 M), or both inhibitors. 
Apoptosis was assessed by caspase 3/7 activity. **P < 0.01; t-test in 
(A), ANOVA with Bonferroni post hoc correction in (E).
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miR-34a and for cholangiocyte lipoapoptosis in an animal 
model of NASH. Further, these results suggest that upregu-
lation of miR-34a plays an important role in cholangiocyte 
lipoapoptosis in a cell culture model and potentially in bili-
ary injury during NASH.
DISCUSSION
Increased FFAs in the circulation during metabolic syn-
drome or NASH have fatal consequences in the liver by 
inducing cholangiocyte and hepatocyte lipoapoptosis (27, 
28). Increased plasma FFAs have been observed in pa-
tients with NAFLD or the associated condition of metabolic 
syndrome. Plasma FFAs in 27 out of 47 NASH patients were 
elevated with a mean of 752 M in NASH patients (29). De 
Almeida et al. (30) showed that total plasma FFAs were 350 
M in controls and 563 M in NASH patients. Further, 
saturated FFA levels were 200 M in controls and 316 M 
in NASH patients. Control patients similarly had 460 M 
FFA levels, compared with NASH patients at 660 M (31). 
Recently, Zhang et al. (32) found that control patients had 
450 M plasma FFAs compared with 650 M in NAFLD 
patients. Further, patients with evidence of advanced fibro-
sis had higher FFA levels (720 M) than patients without 
evidence of advanced fibrosis (580 M). From these stud-
ies, the range for controls was 350–460 M FFAs, while 
patients had 563–752 M circulating FFAs. These are total 
levels of all FFAs combined. In our study, we have utilized a 
specific saturated FFA, PA, to reduce complexity and inves-
tigate specific signaling pathways. We chose this fatty acid 
because it is the most common saturated FFA in the circu-
lation [approximately 28% of the total FFAs (33), with a 
range of 300–4,100 M in one study (34)]. Thus, our stud-
ies at 200–800 M fall within the pathologic range of FFA 
concentrations.
The principal finding of this study is that PA, the pre-
dominant circulating FFA, induced cholangiocyte lipo-
apoptosis via FoxO3-dependent induction of pro-apoptotic 
miR-34a. Our data suggest three important findings in 
cholangiocyte lipoapoptosis caused due to PA exposure: 1) 
PA upregulates pro-apoptotic miR-34a in a FoxO3-depen-
dent manner to cause cholangiocyte lipoapoptosis; 2) in-
creased miR-34a expression targets protein deacetylase 
SIRT1 as well as several anti-apoptotic proteins; and 3) 
cholangiocyte lipoapoptosis and miR-34a upregulation 
due to lipotoxicity were also evident in an animal model of 
NASH. The proposed model for FFA-induced cholangio-
cyte lipoapoptosis is shown in Fig. 8. These results will be 
discussed in the following paragraphs.
Biliary injury and cholestatic NASH have been docu-
mented at least in a subset of patients with NAFLD (3). Our 
earlier work showed implications for biliary injury in re-
sponse to FFAs and demonstrated the mechanism of 
Fig. 7. Cholangiocyte lipoapoptosis in animal model 
of NASH. A: A Masson trichrome-stained liver section 
from HFHS-fed mice showed enhanced lipid droplet 
and collagen accumulation compared with chow-fed 
control (Con) mice. B: Total RNA was isolated from 
flash-frozen liver tissue and miR-34a levels were mea-
sured relative to RNU6. C: Cholangiocytes were identi-
fied by pan-keratin staining and apoptotic nuclei were 
identified in the same section by TUNEL reaction. 
TUNEL-positive cholangiocytes are indicated as a per-
centage of total cholangiocyte nuclei. A total of 900–
3,000 cholangiocytes were scored per sample. Data 
represent the mean ± SEM for n = 4 mice for each 
group. *P < 0.05, t-test.
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FFA-induced cholangiocyte lipoapoptosis involving the ac-
tivation and nuclear translocation of FoxO3. Activation of 
FoxO3 with saturated FFAs thereby increased the expres-
sion of its downstream target, PUMA, a pro-apoptotic BH3-
domain-containing protein, resulting in caspase-dependent 
cholangiocyte lipoapoptosis (4, 5). RNAi-mediated inhibi-
tion of PUMA protected cells partially, but not completely 
(5). Here, we extended our work to demonstrate the role 
for pro-apoptotic miR-34a in cholangiocyte lipoapoptosis. 
miR-34a has been shown to be upregulated in the liver 
from patients with NASH (15). Circulating levels of miR-
34a were also shown to be elevated in patients with NAFLD, 
NASH, diabetes, obesity, and alcoholic liver disease (18, 25, 
35). In the present study, we elucidated the mechanism of 
miR-34a upregulation. Our data also indicate that miR-34a 
upregulation with saturated FFA is a common process for 
both cholangiocyte- and hepatocyte-derived cells. Further, 
transfection of an antisense oligonucleotide against miR-34a 
prevented cholangiocyte lipoapoptosis due to PA exposure. 
Caspase 3 activation has been suggested to lead to cleavage 
of Dicer, a microRNA processing enzyme in the cytosol 
(36). However, we observed a dramatic increase in mature 
miR-34a levels with PA treatment in a panel of cholangio-
cytes tested, suggesting that Dicer is either not degraded in 
lipoapoptosis or it is not limiting for microRNA processing. 
We know that both cholangiocytes and hepatocytes are de-
rived from a common progenitor cell. We observed that 
miR-34a upregulation was not solely occurring in cholan-
giocytes, but was also seen in Huh-7 cells. The increase in 
total hepatic miR-34a, either in our HFHS mice or in studies 
on NASH miRs (15), is likely to be dominated by hepato-
cyte-derived miR-34a, as hepatocytes comprise the majority 
of the cells in the liver. Whether miR-34a upregulation with 
FFAs in hepatocytes occurs in a similar FoxO3-dependent 
fashion, as in cholangiocytes, remains to be tested.
Our previous study implicated FoxO3 activation and 
nuclear translocation in cholangiocyte lipoapoptosis (5). 
We also reported that acetylated FoxO3 accumulated in 
the nuclear fraction in saturated FFA-treated cells (5). We 
speculated before that increased acetylation of FoxO3 
might be due to a decrease in SIRT1 protein levels (5). 
Loss of SIRT1 has also been shown to be associated with 
insulin resistance (37, 38). Here we found that miR-34a tar-
geted SIRT1 protein. SIRT1 is a protein deacetylase and 
acetylated FoxO3 is a known SIRT1 substrate (39, 40), so 
decreased SIRT1 can enhance the acetylation status of 
FoxO3. Acetylated FoxO3 was shown to be pro-apoptotic in 
nature and could induce downstream targets, like BIM and 
PUMA. Interestingly, we found that FoxO3 is responsible 
for the upregulation of miR-34a upon PA treatment. FoxO3 
can increase Bcl-2 expression under normal conditions 
and in alcoholic liver disease, while acetylated-FoxO3 has 
been shown to have lost this protective function (41). Thus, 
the increased acetylated FoxO3 in cholangiocytes exposed 
to PA might have lost a Bcl-2-dependent protective func-
tion, instead becoming pro-apoptotic in nature.
Mature miR-34a has sequence complementarity to the 3′ 
UTR of SIRT1 mRNA. NAFLD severity in human and ani-
mal models was shown to be positively correlated with the 
levels of miR-34a and inversely correlated with SIRT1 pro-
teins levels (14). Treatment with ursodeoxycholic acid 
(UDCA) prevents the upregulation of miR-34a in total liver 
and primary hepatocytes (14). UDCA has been shown to 
upregulate the expression of SIRT1 to deacetylate p53, a 
miR-34a activator. Further, UDCA prevents posttransla-
tional modification of p53 and reduces its transcriptional 
activity (14). Our results suggest that PA-induced miR-34a 
upregulation is independent of p53 transcriptional activity. 
Specifically, we observed a similar increase in miR-34a lev-
els in both normal cholangiocytes and malignant-derived 
cholangiocytes that were confirmed by sequencing to have 
p53 inactivating mutants (data not shown). Using an in-
hibitor of SIRT1, we enhanced cytotoxicity of low-dose PA, 
demonstrating that loss of SIRT1 expression increased cell 
injury. SIRT1 deacetylase activity has been shown to have a 
role in the miR-34a promoter acetylation (9). Loss of SIRT1 
results in failure of the miR-34a promoter to be deacety-
lated, which could possibly enhance FoxO3 transcriptional 
activation of miR-34a (9). Additionally, SIRT1 can deacety-
late various other transcription factors, like FXR, SREBPs, 
PPARs, PGC1, LXR, FoxO1, and FoxO3 (39, 42, 43). 
Deacetylation of FXR, LXR, PPARs, and PGC1 can acti-
vate their downstream targets with key roles in bile acid, 
cholesterol, lipid, and energy homeostasis (44). In con-
trast, deacetylation of SREBP can prevent its transcriptional 
activity (44). Whether these altered transcription factors 
have a role in cholangiocyte lipoapoptosis needs further 
investigation.
KLF4 is a zinc-finger transcription factor, tumor suppres-
sor, and embryonic progenitor cell differentiation factor 
(45). KLF4 has been shown to act as a radio-protector 
against apoptotic insults (46). KLF4-deficient cells had de-
creased levels of the multi-domain Bcl-2 family proteins, 
Mcl-1 and Bcl-XL (BCLXL) (47). Further, KLF4 was shown 
Fig. 8. Schematic diagram of the proposed role of miR-34a in PA-
induced cholangiocyte lipoapoptosis. The saturated FFA, PA, in-
creased nuclear FoxO3 levels leading to increased miR-34a in 
PA-treated cells. miR-34a then promoted lipoapoptosis, likely 
through decreasing protein levels of its targets, SIRT1, MET, and 
KLF4. Based on literature reports of SIRT1 activity on FoxO3 and 
our previous finding of increased nuclear acetylated-FoxO3, we 
speculate that a miR-34a-mediated decrease in SIRT1 may enhance 
FoxO3 acetylation levels.
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to have transcriptional activity in the MCL1 promoter re-
gion (47). PA-induced miR-34a decreased KLF4 levels in 
cholangiocyte-derived cells. Based on miR-34a regulation 
of KLF4 in the literature (6), KLF4 may be performing an 
anti-apoptotic role in cholangiocytes that is lost upon FFA 
treatment. We also observed that MET a receptor tyrosine 
kinase and hepatocyte growth factor receptor, is another 
anti-apoptotic protein targeted by miR-34a that was found 
to be decreased in cholangiocytes exposed to FFA. MET is 
well-known to activate Akt and Stat3 cell survival pathways 
(48). Additionally, the cell survival mechanism of MET also 
involves sequestering Fas to block apoptosis and prevent 
degradation of the anti-apoptotic regulator, FLIPL (long 
splice form of FLICE inhibitor protein) (49). Normally, 
FLIP binds to Fas-associated death domain, a common pro-
tein for both Fas and death receptor complexes, and forms 
an apoptosis inhibitory complex that prevents the activa-
tion of pro-caspases (49). Further studies are needed to 
elucidate whether loss of KLF4 or MET is critical for chol-
angiocyte lipoapoptosis, but a MET inhibitor did not en-
hance killing.
Treatment with a miR-34a inhibitor has been suggested 
to be a novel therapeutic strategy for NAFLD (50). Silenc-
ing of miR-34a using a miR-34a inhibitor was shown to pre-
vent liver injury and improve hepatic steatosis through its 
target proteins, like PPAR and SIRT1, which can activate 
AMP-activated protein kinase in an animal model of 
NAFLD (50). Additionally, FGFR signaling promotes cell 
survival (26), such that any loss of FGFR expression due to 
saturated FFA, through increased miR-34a, could promote 
lipoapoptosis. One of the downstream signaling pathways 
of FGFRs is Akt, and miR-34a targeting of FGFRs may de-
crease the levels of Akt that can affect the phosphorylation 
status of FoxO3 and AMP-activated protein kinase, as re-
ported before (50). Ectopic miR-34a expression has been 
shown to decrease basal Akt phosphorylation and several 
proteins that regulate cell cycle that help in G1/S transi-
tion, like CKD4, CKD6, CCND1, CCNE2, and E2F3 (51). 
These observations further support our hypothesis that 
miR-34a is critical for cholangiocyte lipoapoptosis.
Our current and previous work demonstrates that satu-
rated FFA induced cholangiocyte lipoapoptosis. We also 
observed that increased cholangiocyte lipoapoptosis was 
present in the nutrient-excess model for NASH. This model 
mimics a Western diet containing high saturated fats, cho-
lesterol, and sucrose and shows similar characteristics to 
human NASH, such as ballooned hepatocytes, massive 
lipid droplet accumulation, increased collagen accumula-
tion, increased -smooth muscle actin expression, and in-
creased pro-inflammatory cytokines in the liver. We 
observed enhanced levels of miR-34a in mice fed the HFHS 
diet, consistent with a role for miR-34a in the lipoapoptosis 
of NASH. A recent study showed that lentiviral injection of 
miR-34a inhibitor resulted in protection against liver injury 
(50). We predict that treatment with a miR-34a inhibitor 
might also prevent cholangiocyte lipoapoptosis. Further 
studies are required to elucidate whether cholangiocyte li-
poapoptosis contributes to or promotes the progression of 
NASH, at least in a subset of cholestatic NAFLD patients.
In conclusion, our results show that PA-induced cholan-
giocyte lipoapoptosis involved the activation of pro-apoptotic 
miR-34a, dependent on FoxO3. miR-34a targeted protein 
deacetylase, SIRT1, and anti-apoptotic proteins. Further, 
cholangiocyte lipoapoptosis was also evident in an animal 
model of NASH.
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